Systems and methods for personalized de-risking based on patient genome data

US9779214B2 · kind B2 · utility

Assignee

• Molecular Health GmbH · DE

Inventors

• David Brian Jackson · Spanish Fork, US
• Theodoros Soldatos · Heidelberg, DE
• Guillaume Taglang · Heidelberg, DE
• Alexander Zien · Heidelberg, DE
• Stephan Brock · Weinheim, DE

Key dates

• Filing date: Apr 13, 2012
• Grant date: Oct 3, 2017
• Expiry date: Apr 13, 2032

Classification

• Technology area (CPC G): Physics
• CPC primary: G16H70/40
• WIPO field: Medical technology
• WIPO sector: Instruments

Abstract

The present disclosure describes systems and methods for using patient-specific genomic information to optimize or de-risk therapy for the patient. A user may identify a medication for consideration for prescription to a patient, and a genetic variant of the patient affecting a first protein. An analyzer may identify a second medication targeting the first protein, and may retrieve adverse event data from an adverse event database for patients co-medicated with both the first medication and second medication. The analyzer may determine, based on rates of adverse events, the likelihood of an adverse event occurring through co-medication of the first medication and second medication. Based on the likelihood, and based on a correspondence or non-correspondence between a protein activation characteristic of the first medication and the effect of the genetic variant of the patient, the analyzer may indicate or contra-indicate the first medication for the patient.